Skip to content
Case report Open access

Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer

Oct 2026 · Frontiers in Oncology · Vol 16 · 0 citations · 12 references
Medicine

Abstract

The median overall survival (OS) for patients with recurrent or metastatic cervical cancer after progression on first-line therapy is only 5–12 months. We retrospectively reviewed four patients who received modified induction–maintenance therapy. All of the patients achieved clinical benefit to varying degrees, with one attaining progression-free survival (PFS) of over 58 months and an OS of 86 months. However, these findings should be interpreted with caution and warrant validation in larger prospective studies.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.